Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study
To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts bet...
Saved in:
Published in | Diabetes care Vol. 41; no. 1; pp. 171 - 177 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Diabetes Association
01.01.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement.
We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement.
Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98],
< 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511,
< 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality.
The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality. |
---|---|
AbstractList | To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement.OBJECTIVETo examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement.We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement.RESEARCH DESIGN AND METHODSWe conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement.Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality.RESULTSMedian age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality.The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.CONCLUSIONSThe 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality. To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality. OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS We conducted a prospective population-based cohort study of 4,867men, randomly selected fromprespecified birth cohorts between 1921 and 1949,who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, andmortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. RESULTS Median agewas 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associatedwith incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-hmeasurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. CONCLUSIONS The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality. OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (=8.6 mmol/L) versus 2-h (=7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. RESULTS Median age was 48 years (interquartile range [IQR] 48-49). During follow-up (median 33 years [IQR 24-37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90-3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. CONCLUSIONS The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality. |
Author | Pareek, Manan Eriksson, Karl-Fredrik Bergman, Michael Nielsen, Mette L. Nilsson, Peter M. Bhatt, Deepak L. Jagannathan, Ram Olsen, Michael H. |
Author_xml | – sequence: 1 givenname: Manan orcidid: 0000-0002-0867-5825 surname: Pareek fullname: Pareek, Manan organization: Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark, Cardiology Section, Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark – sequence: 2 givenname: Deepak L. surname: Bhatt fullname: Bhatt, Deepak L. organization: Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA – sequence: 3 givenname: Mette L. surname: Nielsen fullname: Nielsen, Mette L. organization: Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark – sequence: 4 givenname: Ram surname: Jagannathan fullname: Jagannathan, Ram organization: Center for Healthful Behavior Change, Department of Population Health, New York University School of Medicine, New York, NY – sequence: 5 givenname: Karl-Fredrik surname: Eriksson fullname: Eriksson, Karl-Fredrik organization: Department of Clinical Sciences and Lund University Diabetes Centre, Lund University, Skåne University Hospital, Malmö, Sweden – sequence: 6 givenname: Peter M. surname: Nilsson fullname: Nilsson, Peter M. organization: Department of Clinical Sciences and Lund University Diabetes Centre, Lund University, Skåne University Hospital, Malmö, Sweden – sequence: 7 givenname: Michael surname: Bergman fullname: Bergman, Michael organization: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and Diabetes Prevention Program, New York University Langone Health, New York University School of Medicine, New York, NY – sequence: 8 givenname: Michael H. surname: Olsen fullname: Olsen, Michael H. organization: Cardiovascular and Metabolic Preventive Clinic, Department of Endocrinology, Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark, Cardiology Section, Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29138275$$D View this record in MEDLINE/PubMed https://lup.lub.lu.se/record/c425b721-e539-4e88-8475-dd9c4af51632$$DView record from Swedish Publication Index oai:portal.research.lu.se:publications/c425b721-e539-4e88-8475-dd9c4af51632$$DView record from Swedish Publication Index |
BookMark | eNqNksFrFDEUxoNU7LZ68B-QgBc9jE0mySTxVpfaCgstuJ5DJvOGTclOxmSmsv-92e7WQ0XwEHL5ve99fO87QydDHACht5R8qhmTF52jsqJM0BdoQTUTlRBcnaAFoVxXQuv6FJ3lfE8I4VypV-i01pSpWooFylfDxg4OOnyXoPNu8g-Al3a0rQ9-2uHYY4tpdRPnhG-TDfg6zC5mwOsYIO0n8Rry9BlfFoGYRzgo3MVxDnbycai-2FzUl3ET04S_T3O3e41e9jZkeHP8z9GPr1fr5U21ur3-trxcVU4wNVUdp9BKLhVVUnbaOa2BOdvXLZOEqEbUTnStAk1aanXvNCeNLlG4FppeK8fOkT3o5l8wzq0Zk9_atDPRejMWNzaYBBlschsTZpPBFCp49-g7G8dr0cqaGhBMGw5KGcWlMF3xwm0vaMPqsmP1zx1hHstrj9r_KffhIDem-HMuwZqtzw5CsAPEORuqGy5JXe5Y0PfP0PtypKEEWihNFG1E0xTq3ZGa2y10f_w9NaAAFwfAlfPlBL1xfnpMYErWB0OJ2XfM7Dtm9h0rEx-fTTyJ_s3-Bm050Ik |
CitedBy_id | crossref_primary_10_1177_11795514231177206 crossref_primary_10_4158_EP_2019_0387 crossref_primary_10_3390_biomedicines12020363 crossref_primary_10_1111_jdi_14308 crossref_primary_10_1007_s15006_018_0328_0 crossref_primary_10_2337_dc19_1975 crossref_primary_10_3389_fgwh_2024_1391213 crossref_primary_10_1155_2022_4875993 crossref_primary_10_3390_nu17010152 crossref_primary_10_1016_j_diabres_2021_108650 crossref_primary_10_1111_pedi_12803 crossref_primary_10_1016_j_diabres_2024_111941 crossref_primary_10_1186_s12967_019_1787_5 crossref_primary_10_1016_j_ctim_2019_102280 crossref_primary_10_1016_j_amepre_2019_07_021 crossref_primary_10_1111_jdi_13213 crossref_primary_10_1186_s12902_018_0286_7 crossref_primary_10_3389_fendo_2023_1260623 crossref_primary_10_1210_jc_2018_02166 crossref_primary_10_2337_db24_0652 crossref_primary_10_1152_physrev_00015_2022 crossref_primary_10_3390_genes13122277 crossref_primary_10_1007_s11695_021_05259_3 crossref_primary_10_1371_journal_pone_0246568 crossref_primary_10_1016_j_diabres_2021_108883 crossref_primary_10_1016_j_diabres_2024_111856 crossref_primary_10_1016_j_heliyon_2025_e42880 crossref_primary_10_1016_j_diabres_2024_111973 crossref_primary_10_1016_j_numecd_2021_10_016 crossref_primary_10_1111_jdi_13245 crossref_primary_10_30682_ildia1901a crossref_primary_10_1016_j_jcf_2019_07_006 crossref_primary_10_1007_s40618_023_02111_6 crossref_primary_10_3390_biomedicines11123242 crossref_primary_10_1136_bmjdrc_2019_000837 crossref_primary_10_1111_pedi_12700 crossref_primary_10_1016_j_diabres_2022_109980 crossref_primary_10_2337_dc17_2530 crossref_primary_10_1210_clinem_dgac017 crossref_primary_10_3389_fendo_2022_871965 crossref_primary_10_1016_j_dsx_2022_102630 crossref_primary_10_1016_j_diabres_2024_111963 crossref_primary_10_2337_dc20_1688 crossref_primary_10_2147_JMDH_S493128 crossref_primary_10_1507_endocrj_EJ23_0227 crossref_primary_10_1016_j_diabres_2021_109156 crossref_primary_10_2337_dc22_1894 crossref_primary_10_1038_s41440_021_00749_4 crossref_primary_10_1016_j_diabet_2022_101395 crossref_primary_10_2337_dc18_0279 crossref_primary_10_31083_j_ceog4910219 crossref_primary_10_7197_cmj_1170079 crossref_primary_10_1210_clinem_dgae748 crossref_primary_10_1080_07853890_2021_1902557 crossref_primary_10_1016_j_diabres_2025_112056 crossref_primary_10_3389_fcvm_2022_947292 crossref_primary_10_1007_s12020_022_03109_5 crossref_primary_10_14341_DM12656 crossref_primary_10_1017_S0007114521004153 crossref_primary_10_1016_j_mmm_2020_06_022 crossref_primary_10_1038_s41387_019_0084_y crossref_primary_10_2337_dc17_2714 crossref_primary_10_1016_j_diabres_2020_108075 crossref_primary_10_2337_dc17_1900 crossref_primary_10_1111_dme_14330 crossref_primary_10_1016_j_diabres_2020_108233 crossref_primary_10_1210_jc_2018_01828 crossref_primary_10_1159_000515730 crossref_primary_10_1515_jpem_2021_0745 crossref_primary_10_3390_jcm13175200 crossref_primary_10_1016_j_diabres_2024_111589 crossref_primary_10_1177_1479164119896978 crossref_primary_10_1093_eurheartj_ehad192 crossref_primary_10_1007_s42000_022_00359_w crossref_primary_10_1210_jc_2018_00468 crossref_primary_10_1002_dmrr_3096 crossref_primary_10_1136_bmjdrc_2019_001156 crossref_primary_10_3390_ijerph20115961 crossref_primary_10_3390_ijerph20010787 crossref_primary_10_1016_j_diabres_2023_110839 crossref_primary_10_1016_j_dsx_2019_06_029 crossref_primary_10_1016_j_diabres_2021_108683 crossref_primary_10_1186_s13098_023_01039_4 crossref_primary_10_1007_s00125_018_4798_5 crossref_primary_10_1016_S2213_8587_18_30234_1 crossref_primary_10_3390_jcm11144124 crossref_primary_10_1016_j_metabol_2024_155910 crossref_primary_10_1186_s12933_022_01590_w crossref_primary_10_1016_j_diabres_2025_112075 crossref_primary_10_1055_a_1516_3850 crossref_primary_10_1007_s00592_022_01963_3 crossref_primary_10_1111_dom_13640 crossref_primary_10_1002_dmrr_2992 crossref_primary_10_1007_s00592_018_1105_3 crossref_primary_10_1016_j_diabres_2018_09_017 crossref_primary_10_1016_j_lanwpc_2024_101278 crossref_primary_10_1016_j_diabres_2021_109004 crossref_primary_10_1210_jendso_bvac055 crossref_primary_10_1016_j_metop_2022_100200 crossref_primary_10_1038_s41598_021_87266_z crossref_primary_10_1016_j_numecd_2020_06_020 crossref_primary_10_1016_j_jdiacomp_2023_108551 crossref_primary_10_1210_clinem_dgae632 crossref_primary_10_3390_molecules26051393 crossref_primary_10_1016_j_diabres_2020_108009 |
Cites_doi | 10.1056/NEJMcp1103643 10.1016/S0895-4356(97)00201-1 10.1016/j.atherosclerosis.2009.04.006 10.1016/S0140-6736(02)08905-5 10.1089/dia.2013.0025 10.2337/dc11-2181 10.1001/archinternmed.2011.183 10.1530/EJE-15-1221 10.1046/j.1365-2796.2000.00568.x 10.1016/j.annepidem.2005.10.008 10.2337/diab.27.1.42 10.2337/diab.28.12.1039 10.1371/journal.pone.0044470 10.1007/BF00400196 10.1056/NEJM200105033441801 10.2337/diab.19.11.852 10.2337/dc12-2625 10.1001/jama.1982.03320430047030 10.1007/s00125-014-3390-x 10.1161/CIRCULATIONAHA.114.014796 10.2337/dc06-1331 10.1210/jc.2012-3971 10.1002/dmrr.728 10.2337/dc08-1264 10.2337/diacare.2.2.105 10.1016/0006-2944(70)90093-1 10.1007/BF00404139 10.2337/dc10-0433 10.1136/bmj.i6538 10.1210/jc.2015-2573 10.1002/sim.4085 10.1056/NEJMoa012512 10.1001/archinternmed.2011.275 10.1046/j.1464-5491.2002.00835.x 10.1007/s001250051024 10.2337/dc08-0225 10.2337/dc11-0155 10.2337/dc10-1581 10.1016/j.diabres.2016.08.013 |
ContentType | Journal Article |
Copyright | 2017 by the American Diabetes Association. Copyright American Diabetes Association Jan 1, 2018 |
Copyright_xml | – notice: 2017 by the American Diabetes Association. – notice: Copyright American Diabetes Association Jan 1, 2018 |
CorporateAuthor | Lunds universitet Profile areas and other strong research environments Translational Muscle Research Department of Clinical Sciences, Malmö Lund University Translationell muskelforskning Strategiska forskningsområden (SFO) EpiHealth: Epidemiology for Health Faculty of Medicine Internmedicin - epidemiologi Strategic research areas (SRA) Medicinska fakulteten Profilområden och andra starka forskningsmiljöer Institutionen för kliniska vetenskaper, Malmö Internal Medicine - Epidemiology |
CorporateAuthor_xml | – name: Faculty of Medicine – name: Medicinska fakulteten – name: Strategiska forskningsområden (SFO) – name: Translationell muskelforskning – name: EpiHealth: Epidemiology for Health – name: Institutionen för kliniska vetenskaper, Malmö – name: Internal Medicine - Epidemiology – name: Strategic research areas (SRA) – name: Lunds universitet – name: Translational Muscle Research – name: Profilområden och andra starka forskningsmiljöer – name: Lund University – name: Profile areas and other strong research environments – name: Internmedicin - epidemiologi – name: Department of Clinical Sciences, Malmö |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 ADTPV AOWAS D95 |
DOI | 10.2337/dc17-1351 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic SwePub SwePub Articles SWEPUB Lunds universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1935-5548 |
EndPage | 177 |
ExternalDocumentID | oai_portal_research_lu_se_publications_c425b721_e539_4e88_8475_dd9c4af51632 oai_lup_lub_lu_se_c425b721_e539_4e88_8475_dd9c4af51632 29138275 10_2337_dc17_1351 |
Genre | Journal Article |
GroupedDBID | --- -ET ..I .XZ 08P 0R~ 18M 29F 2WC 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAIKC AAMNW AAWTL AAYEP AAYXX ABOCM ABPPZ ACGFO ACGOD ADBBV AEGXH AENEX AERZD AFOSN AFRAH AHMBA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EJD EMOBN EX3 F5P GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO KQ8 L7B M0K M5~ O5R O5S O9- OK1 OVD P2P PCD Q2X RHI SV3 TDI TEORI TR2 TWZ VVN W8F WH7 WOQ WOW YHG YOC ~KM .55 .GJ 3O- 41~ 7RV 7X2 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 AAKAS AAQOH AAQQT AAYJJ ABUWG ADZCM AFFNX AFKRA AI. AN0 AQUVI ATCPS AZQEC BCR BCU BEC BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C1A CCPQU CGR CUY CVF DWQXO ECM EIF FYUFA GNUQQ GUQSH HCIFZ HMCUK IAG ITC J5H K9- M0R M0T M1P M2O M2P M2Q N4W NAPCQ NPM PEA PHGZT PQQKQ PROAC PSQYO S0X SJFOW UKHRP VH1 WHG X7M ZCG ZGI ZXP K9. 7X8 ADTPV AOWAS D95 PHGZM PJZUB PPXIY |
ID | FETCH-LOGICAL-c538t-d41eb74781877d9cc99e3caf2b37008652c5db8e90b1a9fc94069dc1cbe6f98c3 |
ISSN | 0149-5992 1935-5548 |
IngestDate | Thu Aug 21 06:43:58 EDT 2025 Thu Jul 03 05:23:46 EDT 2025 Fri Jul 11 02:47:53 EDT 2025 Mon Jun 30 16:46:13 EDT 2025 Thu Apr 03 07:05:02 EDT 2025 Thu Apr 24 23:12:33 EDT 2025 Tue Jul 01 04:11:53 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2017 by the American Diabetes Association. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c538t-d41eb74781877d9cc99e3caf2b37008652c5db8e90b1a9fc94069dc1cbe6f98c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-0867-5825 |
PMID | 29138275 |
PQID | 1990816566 |
PQPubID | 47715 |
PageCount | 7 |
ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_c425b721_e539_4e88_8475_dd9c4af51632 swepub_primary_oai_lup_lub_lu_se_c425b721_e539_4e88_8475_dd9c4af51632 proquest_miscellaneous_1964702044 proquest_journals_1990816566 pubmed_primary_29138275 crossref_citationtrail_10_2337_dc17_1351 crossref_primary_10_2337_dc17_1351 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-01-01 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Alexandria |
PublicationTitle | Diabetes care |
PublicationTitleAlternate | Diabetes Care |
PublicationYear | 2018 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
References | Sayetta (2022031301255071500_B45) 1979; 2 2022031301255071500_B41 Berglund (2022031301255071500_B23) 2000; 247 Tuomilehto (2022031301255071500_B3) 2001; 344 Eriksson (2022031301255071500_B22) 1998; 41 Unwin (2022031301255071500_B9) 2002; 19 2022031301255071500_B24 Chiasson (2022031301255071500_B5) 2002; 359 Fiorentino (2022031301255071500_B15) 2015; 100 Abdul-Ghani (2022031301255071500_B12) 2008; 31 Orencia (2022031301255071500_B32) 1997; 50 Bianchi (2022031301255071500_B20) 2013; 98 Strandberg (2022031301255071500_B34) 2011; 171 Cavender (2022031301255071500_B2) 2015; 132 American Diabetes Association (2022031301255071500_B8) 2016; 39 Alyass (2022031301255071500_B16) 2015; 58 Bergman (2022031301255071500_B18) 2016; 120 Sciacqua (2022031301255071500_B31) 2012; 7 2022031301255071500_B38 Meisinger (2022031301255071500_B33) 2006; 16 de Nobel (2022031301255071500_B42) 1978; 27 Saito (2022031301255071500_B6) 2011; 171 Succurro (2022031301255071500_B29) 2009; 207 Eriksson (2022031301255071500_B21) 1991; 34 Sciacqua (2022031301255071500_B30) 2011; 34 Pencina (2022031301255071500_B28) 2011; 30 Balkau (2022031301255071500_B39) 2011; 34 Eriksson (2022031301255071500_B25) 1990; 33 2022031301255071500_B35 Sisk (2022031301255071500_B40) 1970; 19 Abdul-Ghani (2022031301255071500_B10) 2007; 30 National Diabetes Data Group (2022031301255071500_B43) 1979; 28 Abdul-Ghani (2022031301255071500_B13) 2009; 32 Nielsen (2022031301255071500_B17) 2016; 174 Dankner (2022031301255071500_B11) 2007; 23 American Diabetes Association (2022031301255071500_B1) 2013; 36 Inzucchi (2022031301255071500_B7) 2012; 367 Priya (2022031301255071500_B14) 2013; 15 Knowler (2022031301255071500_B4) 2002; 346 Marini (2022031301255071500_B19) 2012; 35 Barry (2022031301255071500_B37) 2017; 356 2022031301255071500_B26 Harrell (2022031301255071500_B27) 1982; 247 Carroll (2022031301255071500_B44) 1970; 4 Olson (2022031301255071500_B36) 2010; 33 29582286 - MMW Fortschr Med. 2018 Mar;160(Suppl 1):29 29678871 - Diabetes Care. 2018 May;41(5):e81 |
References_xml | – volume: 367 start-page: 542 year: 2012 ident: 2022031301255071500_B7 article-title: Clinical practice. Diagnosis of diabetes publication-title: N Engl J Med doi: 10.1056/NEJMcp1103643 – volume: 50 start-page: 1369 year: 1997 ident: 2022031301255071500_B32 article-title: One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(97)00201-1 – ident: 2022031301255071500_B35 – volume: 207 start-page: 245 year: 2009 ident: 2022031301255071500_B29 article-title: Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2009.04.006 – volume: 359 start-page: 2072 year: 2002 ident: 2022031301255071500_B5 article-title: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08905-5 – volume: 15 start-page: 497 year: 2013 ident: 2022031301255071500_B14 article-title: 1-hour venous plasma glucose and incident prediabetes and diabetes in Asian indians publication-title: Diabetes Technol Ther doi: 10.1089/dia.2013.0025 – volume: 35 start-page: 868 year: 2012 ident: 2022031301255071500_B19 article-title: Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels publication-title: Diabetes Care doi: 10.2337/dc11-2181 – volume: 171 start-page: 941 year: 2011 ident: 2022031301255071500_B34 article-title: One-hour glucose, mortality, and risk of diabetes: a 44-year prospective study in men publication-title: Arch Intern Med doi: 10.1001/archinternmed.2011.183 – volume: 174 start-page: 591 year: 2016 ident: 2022031301255071500_B17 article-title: Follow-up duration influences the relative importance of OGTT and optimal timing of glucose measurements for predicting future type 2 diabetes publication-title: Eur J Endocrinol doi: 10.1530/EJE-15-1221 – volume: 247 start-page: 19 year: 2000 ident: 2022031301255071500_B23 article-title: Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity publication-title: J Intern Med doi: 10.1046/j.1365-2796.2000.00568.x – volume: 16 start-page: 534 year: 2006 ident: 2022031301255071500_B33 article-title: Postload plasma glucose and 30-year mortality among nondiabetic middle-aged men from the general population: the ERFORT Study publication-title: Ann Epidemiol doi: 10.1016/j.annepidem.2005.10.008 – volume: 27 start-page: 42 year: 1978 ident: 2022031301255071500_B42 article-title: The size of the loading dose as an important determinant of the results of the oral glucose tolerance test: a study in subjects with slightly impaired glucose tolerance publication-title: Diabetes doi: 10.2337/diab.27.1.42 – volume: 28 start-page: 1039 year: 1979 ident: 2022031301255071500_B43 article-title: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance publication-title: Diabetes doi: 10.2337/diab.28.12.1039 – volume: 7 start-page: e44470 year: 2012 ident: 2022031301255071500_B31 article-title: Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension publication-title: PLoS One doi: 10.1371/journal.pone.0044470 – volume: 34 start-page: 891 year: 1991 ident: 2022031301255071500_B21 article-title: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö Feasibility Study publication-title: Diabetologia doi: 10.1007/BF00400196 – volume: 344 start-page: 1343 year: 2001 ident: 2022031301255071500_B3 article-title: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance publication-title: N Engl J Med doi: 10.1056/NEJM200105033441801 – volume: 19 start-page: 852 year: 1970 ident: 2022031301255071500_B40 article-title: Comparison of the 50 and 100 gram oral glucose tolerance test publication-title: Diabetes doi: 10.2337/diab.19.11.852 – volume: 36 start-page: 1033 year: 2013 ident: 2022031301255071500_B1 article-title: Economic costs of diabetes in the U.S. in 2012 publication-title: Diabetes Care doi: 10.2337/dc12-2625 – volume: 247 start-page: 2543 year: 1982 ident: 2022031301255071500_B27 article-title: Evaluating the yield of medical tests publication-title: JAMA doi: 10.1001/jama.1982.03320430047030 – volume: 58 start-page: 87 year: 2015 ident: 2022031301255071500_B16 article-title: Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts publication-title: Diabetologia doi: 10.1007/s00125-014-3390-x – volume: 132 start-page: 923 year: 2015 ident: 2022031301255071500_B2 article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.014796 – volume: 30 start-page: 1544 year: 2007 ident: 2022031301255071500_B10 article-title: What is the best predictor of future type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc06-1331 – volume: 98 start-page: 2100 year: 2013 ident: 2022031301255071500_B20 article-title: Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-3971 – ident: 2022031301255071500_B38 – volume: 39 start-page: S1 year: 2016 ident: 2022031301255071500_B8 article-title: Standards of Medical Care in Diabetes—2016 publication-title: Diabetes Care – volume: 23 start-page: 551 year: 2007 ident: 2022031301255071500_B11 article-title: Predicting the 20-year diabetes incidence rate publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.728 – volume: 32 start-page: 281 year: 2009 ident: 2022031301255071500_B13 article-title: Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study publication-title: Diabetes Care doi: 10.2337/dc08-1264 – volume: 2 start-page: 105 year: 1979 ident: 2022031301255071500_B45 article-title: Summary of current diabetes-related data from the National Center for Health Statistics publication-title: Diabetes Care doi: 10.2337/diacare.2.2.105 – volume: 4 start-page: 171 year: 1970 ident: 2022031301255071500_B44 article-title: A colorimetric serum glucose determination using hexokinase and glucose-6-phosphate dehydrogenase publication-title: Biochem Med doi: 10.1016/0006-2944(70)90093-1 – volume: 33 start-page: 526 year: 1990 ident: 2022031301255071500_B25 article-title: Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases publication-title: Diabetologia doi: 10.1007/BF00404139 – volume: 33 start-page: 2184 year: 2010 ident: 2022031301255071500_B36 article-title: Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria publication-title: Diabetes Care doi: 10.2337/dc10-0433 – volume: 356 start-page: i6538 year: 2017 ident: 2022031301255071500_B37 article-title: Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions publication-title: BMJ doi: 10.1136/bmj.i6538 – volume: 100 start-page: 3744 year: 2015 ident: 2022031301255071500_B15 article-title: One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2015-2573 – volume: 30 start-page: 11 year: 2011 ident: 2022031301255071500_B28 article-title: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers publication-title: Stat Med doi: 10.1002/sim.4085 – volume: 346 start-page: 393 year: 2002 ident: 2022031301255071500_B4 article-title: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin publication-title: N Engl J Med doi: 10.1056/NEJMoa012512 – ident: 2022031301255071500_B24 – ident: 2022031301255071500_B26 – volume: 171 start-page: 1352 year: 2011 ident: 2022031301255071500_B6 article-title: Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial publication-title: Arch Intern Med doi: 10.1001/archinternmed.2011.275 – volume: 19 start-page: 708 year: 2002 ident: 2022031301255071500_B9 article-title: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention publication-title: Diabet Med doi: 10.1046/j.1464-5491.2002.00835.x – volume: 41 start-page: 1010 year: 1998 ident: 2022031301255071500_B22 article-title: No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise publication-title: Diabetologia doi: 10.1007/s001250051024 – volume: 31 start-page: 1650 year: 2008 ident: 2022031301255071500_B12 article-title: One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc08-0225 – volume: 34 start-page: 1406 year: 2011 ident: 2022031301255071500_B30 article-title: One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients publication-title: Diabetes Care doi: 10.2337/dc11-0155 – volume: 34 start-page: 957 year: 2011 ident: 2022031301255071500_B39 article-title: Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c publication-title: Diabetes Care doi: 10.2337/dc10-1581 – volume: 120 start-page: 221 year: 2016 ident: 2022031301255071500_B18 article-title: One-hour post-load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow-up of the Israel Study of Glucose Intolerance, Obesity and Hypertension publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2016.08.013 – ident: 2022031301255071500_B41 – reference: 29678871 - Diabetes Care. 2018 May;41(5):e81 – reference: 29582286 - MMW Fortschr Med. 2018 Mar;160(Suppl 1):29 |
SSID | ssj0004488 |
Score | 2.5548174 |
Snippet | To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the... OBJECTIVE To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications... |
SourceID | swepub proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 171 |
SubjectTerms | Adult Blood Blood Glucose - metabolism Body Mass Index Clinical Medicine Cohort analysis Complications Diabetes Diabetes Complications - blood Diabetes Complications - diagnosis Diabetes Complications - epidemiology Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Diagnostic tests Endocrinology and Diabetes Endokrinologi och diabetes Female Follow-Up Studies Glucose Glucose Intolerance - blood Glucose Intolerance - diagnosis Glucose tolerance Glucose Tolerance Test Hazards Health risk assessment Health risks Humans Kaplan-Meier Estimate Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Mortality Population studies Population-based studies Prevalence Prospective Studies Quantitative analysis Reclassification Regression analysis Research design Risk Assessment Time Factors |
Title | Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29138275 https://www.proquest.com/docview/1990816566 https://www.proquest.com/docview/1964702044 https://lup.lub.lu.se/record/c425b721-e539-4e88-8475-dd9c4af51632 oai:portal.research.lu.se:publications/c425b721-e539-4e88-8475-dd9c4af51632 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLZgkBAXxE5hQAZxQKoCTWI3NrdZCtWgGYrUkUZcLNtxKJpOWnU5wK_nvThbS5EGDomq2LUjvy9vsd9CyJs0YqIvdRZoG_KAJWkWSB2aIMuM6Dnr0l6RYuP0rD88ZycX_KJ1YorRJSvzzv7aGVfyP1SFZ0BXjJL9B8rWg8ID-A30hTtQGO7XovEgn_gD_NECz1sKL6AjkH6Fw-tPH_oYBkMYqvsFA_E_lf7p49nULYpYgTEIBR-cPlrMqqjL7qiu6hUcgpRLgWtMQE0vnA43joGPq51bdCBrTqMWzl36QKC8Ad_hRPuDqGMHIvCyW-86n_1A-ex9itHxqGk50d917nf3Cyjoq_YmRShamxTOM1YZ8wBUF9HmvD7l1QbCPBsNfVmWbfYexUWCgNSCZMXKgu0-sFbzq4LOkcS8ir4ey1Yu7arpJrkVgVmBFS8-f21llwdu5rNP4Uzv63kwY3T5z0315Q-bZCvhbKGkjO-Ru6V1QQ88VO6TGy5_QG6flv4TD8myQgxtEEMbxNBZRjX1iKGIGFoihtaIoYiYD_SAtvBCt_FCPV5ogZdH5PzjYHw0DMqyG4EF6bcKUhY6g2UVQpEkqbRWShdbnUUmTtAC5pHlqRFO9kyoZWYlBk_DWlnj-pkUNn5M9vJZ7p4Sqi2XLHVWM-AJTHCpudO9OI05kzqS_Q55W62msmVOeiyNMlVgmyINFNJAIQ065HXdde4TsezqtF-RRJXf6VKFoHAJTDIF072qm4GL4tGYzt1sjX36LME4cdYhTzwp61kq0nfIwNO2bsHU7NP1HC4Dl1o6ZUEEmiQKleOxVMwJoUD94yqFdWQ642D9RB3ybcc43tpWZYqvSTnevLV3f63Bn_319Z-TO82XuU_2Vou1ewEK9cq8LL6C37VIzRY |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+Predictive+Capability+of+a+1-Hour+Oral+Glucose+Tolerance+Test%3A+A+Prospective+Population-Based+Cohort+Study&rft.jtitle=Diabetes+care&rft.au=Pareek%2C+Manan&rft.au=Bhatt%2C+Deepak+L&rft.au=Nielsen%2C+Mette+L&rft.au=Jagannathan%2C+Ram&rft.date=2018-01-01&rft.eissn=1935-5548&rft.volume=41&rft.issue=1&rft.spage=171&rft_id=info:doi/10.2337%2Fdc17-1351&rft_id=info%3Apmid%2F29138275&rft.externalDocID=29138275 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |